Literature DB >> 34117086

Three FDA advisory panel members resign over approval of Alzheimer's drug.

Elisabeth Mahase1.   

Abstract

Entities:  

Year:  2021        PMID： 34117086     DOI： 10.1136/bmj.n1503

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

Review 1.  Can we learn lessons from the FDA's approval of aducanumab?

Authors:  Kathy Y Liu; Robert Howard
Journal:  Nat Rev Neurol       Date:  2021-09-17       Impact factor: 42.937

Review 2.  Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.

Authors:  Miguel Vaz; Vítor Silva; Cristina Monteiro; Samuel Silvestre
Journal:  Clin Interv Aging       Date:  2022-05-18       Impact factor: 3.829

Review 3.  Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Louis Dwomoh; Gonzalo S Tejeda; Andrew B Tobin
Journal:  Neuronal Signal       Date:  2022-04-21

Review 4.  Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer's Disease Therapeutics.

Authors:  Hyomin Jeong; Heewon Shin; Seungpyo Hong; YoungSoo Kim
Journal:  Exp Neurobiol       Date:  2022-04-30       Impact factor: 3.800

Review 5.  Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.

Authors:  Semira Abdi Beshir; A M Aadithsoorya; Affana Parveen; Sheron Sir Loon Goh; Nadia Hussain; Vineetha Bharathan Menon
Journal:  Int J Alzheimers Dis       Date:  2022-03-09

6.  Aducanumab for Alzheimer's disease?

Authors:  Sebastian Walsh; Richard Merrick; Richard Milne; Carol Brayne
Journal:  BMJ       Date:  2021-07-05

Review 7.  Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer's Disease.

Authors:  Lucie Cahlíková; Rudolf Vrabec; Filip Pidaný; Rozálie Peřinová; Negar Maafi; Abdullah Al Mamun; Aneta Ritomská; Viriyanata Wijaya; Gerald Blunden
Journal:  Molecules       Date:  2021-08-29       Impact factor: 4.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.